Avacta: Christina Coughlin

Avacta has appointed Christina Coughlin as the non-executive director of its board, effective immediately. She is the CEO of CytoImmune Therapeutics, which is developing and commercializing novel cancer immunotherapy products based on engineered allogeneic natural killer cells. Coughlin previously was CMO of Rubius Therapeutics, and before that she was CMO of Tmunity Therapeutics.